Jack A. Khattar - 07 Sep 2023 Form 4 Insider Report for SUPERNUS PHARMACEUTICALS, INC. (SUPN)

Role
President, CEO, Director
Signature
/s/ Timothy C. Dec, as attorney-in-fact
Issuer symbol
SUPN
Transactions as of
07 Sep 2023
Transactions value $
-$539,408
Form type
4
Filing time
07 Sep 2023, 18:00:14 UTC
Previous filing
25 Aug 2023
Next filing
18 Dec 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SUPN Common Stock Options Exercise $0 +35K +4.12% $0.00 884K 07 Sep 2023 Direct F1
transaction SUPN Common Stock Tax liability -$539K -16.8K -1.9% $32.10 867K 07 Sep 2023 Direct F2
holding SUPN Common Stock 1.04M 07 Sep 2023 By the KBT Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SUPN Performance Share Unit Options Exercise $0 -35K -100% $0.00* 0 07 Sep 2023 Common Stock 35K $0.00 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares of common stock received upon the settlement of certain performance share units granted to the Reporting Person on February 23, 2023.
F2 Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the PSU vesting.
F3 On February 23, 2023, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 12, 2023.